论文部分内容阅读
中科院生物物理所刘光慧实验室与北京大学汤富酬实验室及中科院动物研究所曲静实验室合作,首次揭示了人神经干细胞中的基因突变是形成神经胶质母细胞瘤(GBM)的源驱动力,为实现针对携带特定基因突变的神经胶质母细胞瘤的精准治疗提供了新型研究平台和药物评价体系。相关成果12月3日发表于《自然-通讯》。GBM是原发性脑肿瘤中最常见且致死率最高的恶性肿瘤。胶质瘤干细胞(GSC)是存在于
The collaboration of Liu Guanghui Laboratory, Institute of Biophysics, Chinese Academy of Sciences and Tang Fu-jing Laboratory of Peking University and Qujing Laboratory of Institute of Zoology Chinese Academy of Sciences has revealed for the first time that gene mutations in human neural stem cells are the source driver of glioblastoma (GBM) It provides a new research platform and drug evaluation system for the accurate treatment of glioblastoma carrying a specific gene mutation. Relevant results December 3 published in the “Nature - Communications.” GBM is the most common and fatal malignancy in primary brain tumors. Glioma stem cells (GSC) are present in